SlideShare a Scribd company logo
1 of 5
Download to read offline
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/343648002
New Zealand's COVID ‐19 elimination strategy
Article  in  The Medical journal of Australia · August 2020
DOI: 10.5694/mja2.50735
CITATIONS
40
READS
328
3 authors, including:
Some of the authors of this publication are also working on these related projects:
COVID-19 Pandemic View project
Early Clearance of Mycobacterium tuberculosis View project
Amanda Jane Kvalsvig
56 PUBLICATIONS   1,015 CITATIONS   
SEE PROFILE
Ayesha Verrall
University of Otago
38 PUBLICATIONS   729 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Amanda Jane Kvalsvig on 13 May 2021.
The user has requested enhancement of the downloaded file.
MJA
2020
1
Perspective
New Zealand’s COVID-­
19 elimination strategy
Compared with the mitigation and suppression approaches of most Western countries,
elimination can minimise direct health effects and offer an early return to social and economic
activity
O
n 23 March 2020, New Zealand committed
to an elimination strategy in response to the
coronavirus disease 2019 (COVID-­
19) pandemic.
Prime Minister Jacinda Ardern announced that on 26
March, NZ would commence an intense lockdown of
the country (the highest level of a four-­
level response
framework1
). At the time, NZ had just over 100
COVID-­
19 cases and no deaths, so this “go early, go
hard” approach surprised many. However, there were
compelling reasons for NZ to pursue elimination.2
In this article we describe why an elimination strategy
made sense for NZ, the distinguishing features of this
approach, some of the challenges and how they can be
overcome, and where we go from here.
Elimination and other strategic choices
Until early March 2020, the NZ response to COVID-­
19
followed the existing pandemic plan, which was based
on a mitigation approach for managing pandemic
influenza.3
The plan includes steps designed to slow
entry of the pandemic, prevent initial spread and then
apply physical distancing measures progressively
to flatten the curve and avoid overwhelming health
services. Because pandemic influenza cannot be
contained (except by extreme measures such as total
border closure), there was a presumption that case-­
and contact-­
based management would fail and the
country would inevitably progress to widespread
community transmission of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2).
Most Western countries across Europe and North
America were following the mitigation approach.
However, it was performing poorly, with COVID-­
19
cases overwhelming health services. These countries
were then switching to a suppression strategy.4
This
strategy involved intense physical distancing and
travel restrictions (lockdowns) to suppress virus
transmission. A few countries were continuing with
a version of mitigation labelled “herd immunity”, by
which they planned to manage the rate of infection
in such a way as to avoid overwhelming the health
care system and build up enough recovered and
likely immune people in the population to ultimately
interrupt virus transmission. This approach proved
difficult to manage and was largely abandoned (except
perhaps by Sweden).
Most low and middle income countries could do very
little to manage the pandemic except by applying
limited mitigation measures. Vietnam was a notable
exception, implementing stringent control measures
including quarantine, contact tracing, border controls,
school closures and traffic restrictions while case
numbers were still low. A number of island states, such
as Samoa, Tonga and the Cook Islands, adopted an
exclusion approach, primarily by closing their borders
to incoming travellers.
By early March the evidence base for elimination
was growing, with the increasing realisation that
COVID-­
19 was markedly different to pandemic
influenza in terms of its transmission dynamics.5
A watershed moment was the report of the World
Health Organization joint mission to China, which
confirmed that the pandemic there had been contained
even after widespread community transmission had
commenced.6
There was also strong evidence for early
success of the elimination approach in Taiwan,7
Hong
Kong8
and South Korea.9
The concept of elimination is well known to
infectious disease epidemiologists.10
It refers to
the reduction of the incidence of a disease to zero
in a defined geographical area. While absence of
disease is the ultimate goal, elimination criteria for
highly infectious diseases such as measles allow for
occasional outbreaks or imported cases, provided
they are stamped out within a defined time period.11
By contrast, eradication means that the incidence of a
disease has been reduced to zero at the global level, at
least outside laboratories.
There is no established definition for COVID-­
19
elimination. Preliminary thinking suggests that such
a definition would need to include a defined period
of absence of new cases (perhaps 28 days, which is
twice the maximum 14-­
day incubation period).12
This definition would also require a high performing
surveillance system and would exclude cases infected
outside the country and detected in new arrivals
while under isolation or quarantine.12
By late July
2020, NZ had experienced no instances of community-­
based transmission for more than 80 days and could
be considered to have attained elimination. This
status can take weeks or even months to achieve, and
countries could potentially move in and out of this
state depending on their success in containing the
pandemic.
Benefits and costs of elimination
At the time NZ chose an elimination strategy, the
exact nature of this response and its full justification
had not been articulated. The health impact of a
poorly contained pandemic had been modelled using
a range of scenarios,13
demonstrating clear health
gains if a widespread pandemic could be prevented
in NZ. There was also a concern to avoid repeating
the catastrophic impact of previous influenza
pandemics on Māori and to protect neighbouring
Pacific Islands.14
University of Otago,
Wellington, NZ.
michael.baker@
otago.ac.nz
doi: 10.5694/mja2.50735
Michael G Baker
Amanda Kvalsvig
Ayesha J Verrall
2
Perspective
MJA
2020
2
The net economic consequences of an elimination
strategy were uncertain and extremely difficult
to estimate. An additional challenge was that
both the pandemic and its response were likely to
have a disproportionate impact on disadvantaged
populations. While an elimination strategy would
have huge economic and social costs, the alternatives
(suppression and mitigation) would almost certainly
have been far more damaging because of the need to
continue costly physical distancing measures until a
vaccine or other intervention became available.
An advantage of a successful elimination strategy
was that it would provide a medium term exit path
for a return to domestic economic activity without
the constraints of circulating SARS-­
CoV-­
2. Neither
mitigation nor suppression provide a firm exit
strategy, particularly given major uncertainties about
coronavirus immunity and the potential for ongoing
epidemic transmission for months to years under
some scenarios.15
As with all COVID-­
19 strategies, the
ultimate exit path will depend on developing effective
vaccines and therapeutics.
Components of elimination and their
implementation
Elimination requires an array of control measures
tailored to local needs and to the transmission
characteristics of the organism concerned. For
COVID-­
19, the major components are similar to
those used for pandemic control more generally. The
main difference is the intensity and timing of their
application (Box).
COVID-­
19 elimination requires a very strong emphasis
on border management to keep the virus out. That
intervention would usually be combined with case
and contact management to stamp out transmission,
along with highly developed surveillance and testing
to rapidly identify cases and outbreaks. If started
early, these measures may be sufficient for elimination
without the need for lockdowns, as was achieved in
Taiwan.
An elimination strategy requires highly functioning
public health infrastructure. Similar to many
other countries, NZ has supplemented traditional
approaches with newer tools, such as the use of
digital technology to speed up contact tracing.16
The
NZ COVID Tracer app is now operational,17
although
it has yet to be used for contact tracing given the
lack of community cases. Additional surveillance
approaches can be used to provide increased assurance
of elimination (eg, sentinel surveillance, sewage
testing). However, even in the presence of a highly
sophisticated surveillance system, transmission will
continue if isolation and quarantine adherence is
suboptimal.
Barriers to successful elimination and how to
overcome them
The COVID-­
19 pandemic was halted in China,
demonstrating that there are no absolute biological
barriers to its elimination.6
Having no important
animal or environmental reservoirs is a necessary
condition, and this appears to be the case for SARS-­
CoV-­
2 (although its actual origin in nature has not
been determined, so cases could in theory arise from
this source). The combination of high infectiousness
and presymptomatic transmission poses challenges
for control.18
Fortunately, its relatively long incubation
period (about 5 days) makes contact tracing and
quarantining effective, unlike for influenza.5
Components of pandemic control and features that distinguish an elimination strategy from mitigation and
suppression
Pandemic control system component Feature that distinguishes elimination from mitigation and suppression
Planning, coordination and logistics Potentially increased to manage intense elimination measures, including
dedicated agencies, infrastructure and trained public health workforce
Border management, including exclusion, quarantine Increased intensity is critical to creating and sustaining elimination
Case, contact and outbreak management, including
case isolation and contact tracing and quarantine
Increased intensity is critical to creating and sustaining elimination, including
expanded testing capacity and contact tracing systems and workforce
Disease surveillance, including high volume
laboratory testing and sentinel surveillance
Increased intensity is critical to creating and sustaining elimination, including
strong emphasis on rapid, sensitive case identification and additional methods
to confirm elimination
Physical distancing and movement restriction at
various levels (up to lockdown)
Ability to introduce early and intensely to suppress community transmissions
and outbreaks
Public communication to improve hand washing,
cough etiquette, mask wearing, physical distancing
Potentially increased to communicate intense elimination measures
Protecting vulnerable populations Similar, but duration will be shorter if elimination is successful
Primary care capacity Adapted to increase testing capacity
Hospital capacity (eg, expansion of intensive care
unit and ventilator capacity)
Similar, but duration will be shorter and demand less intense if elimination is
successful
Protecting health care workers Similar, but demand will be less intense if elimination is successful
Research and evaluation Potentially increased given limited evidence base for elimination measures
MJA
2020
3
Perspective
MJA
2020
3
Changing human behaviour to reduce transmission
is challenging with a virus as infectious as SARS-­
CoV-­
2. This is why mandated extreme physical
distancing and movement control (lockdown) may
be needed. The intense lockdown carried out in NZ
suppressed transmission and gave the country time to
expand border controls, improve contact tracing, and
undertake large scale testing. Coming out of lockdown
(which began progressively on 28 April) must be
managed carefully, as the goal is to emerge into a
country that is free from community transmission
(unlike the lockdowns in countries pursuing
mitigation or suppression). Widespread use of face
masks was not a feature of the NZ strategy but might
in future reduce the need for lockdowns.19
Successful implementation of an elimination
strategy requires early risk assessment, effective
response planning, infrastructure, resources and
political will. The global response to SARS-­
CoV-­
2
has been described as the “greatest science policy
failure of our generation”.20
An elimination strategy
could potentially have been widely used to contain
COVID-­
19 and protect populations in countries across
the globe.
Where to from here?
NZ and Australia appear to have joined a small group
of countries and jurisdictions pursuing an explicit, or
implied, elimination goal, albeit by different strategies.
Others including mainland China, Hong Kong,
Taiwan, South Korea, Vietnam and a number of small
island states and territories. This set of countries is
likely to expand in the future. It is not hard to imagine
travel between them being relaxed once the risks are
well understood and can be managed. It may be time
for these countries to actively share knowledge and
evidence about the approaches that are supporting
them to contain and eliminate COVID-­
19.
There are multiple potential future scenarios. By
pursuing and maintaining an elimination strategy,
countries can prevent disease and death from
COVID-­
19 and avoid further exacerbation of existing
health inequities. They can also move from having to
manage ongoing pandemic transmission within their
populations to being able to make informed strategic
choices about prevention and control options such as
vaccines and therapeutics as they become available.
Acknowledgements: We thank our many colleagues who have
contributed to development of the NZ elimination strategy, notably
Professor Nick Wilson at the University of Otago, Wellington. We also
acknowledge funding support from the Health Research Council of
NZ (20/1066), which did not have any role in the planning, writing or
publication of the work or the decision to publish.
Competing interests: No relevant disclosures.
Provenance: Commissioned; externally peer reviewed. ■
© 2020 AMPCo Pty Ltd
References are available online.
4
Perspective
MJA
2020
3.e1
	 1	 New Zealand Government. New Zealand
COVID-19 alert levels summary. https://
covid​19.govt.nz/asset​s/COVID_Alert-
levels_v2.pdf (viewed June 2020).
	 2	 Baker M, Kvalsvig A, Verrall A, et al. New
Zealand’s elimination strategy for the
COVID-­
19 pandemic and what is required
to make it work. N Z Med J 2020; 133:
10–14.
	 3	 Ministry of Health. New Zealand
Influenza Pandemic Plan: a framework
for action. 2nd ed. Wellington: Ministry
of Health, 2017. https://www.health.
govt.nz/syste​m/files/​docum​ents/publi​
catio​ns/influ​enza-pande​mic-plan-frame​
work-action-2nd-edn-aug17.pdf (viewed
June 2020).
	 4	 Ferguson NM, Laydon D, Nedjati-Gilani
G, et al. Impact of non-pharmaceutical
interventions (NPIs) to reduce COVID19
mortality and healthcare demand.
London: Imperial College London, 2020.
https://spiral.imper​ial.ac.uk:8443/handl​
e/10044/​1/77482 (viewed June 2020).
	 5	 Anderson RM, Heesterbeek H,
Klinkenberg D, et al. How will country-­
based mitigation measures influence the
course of the COVID-­
19 epidemic? Lancet
2020; 395: 931–934.
	 6	 World Health Organization. Report of the
WHO-China Joint Mission on Coronavirus
Disease 2019 (COVID-19). 16-24 February
2020. Geneva: WHO, 2020. https://www.
who.int/docs/defau​lt-sourc​e/coron​aviru​
se/who-china-joint-missi​on-on-covid-19-
final-report.pdf (viewed July 2020).
	 7	 Wang CJ, Ng CY, Brook RH. Response to
COVID-­
19 in Taiwan: Big Data analytics,
new technology, and proactive testing.
JAMA 2020; 323: 1341–1342.
	 8	 Cowling BJ, Ali ST, Ng TWY, et al. Impact
assessment of non-­
pharmaceutical
interventions against coronavirus disease
2019 and influenza in Hong Kong: an
observational study. Lancet Public Health
2020; 5: e279–e288.
	 9	 Kang J, Jang YY, Kim J, et al. South
Korea’s responses to stop the COVID-­
19
pandemic. Am J Infect Control 2020;.
https://doi.org/10.1016/j.ajic.2020.06.003
[Epub ahead of print].
	
10	 Dowdle WR. The principles of disease
elimination and eradication. Bull World
Health Organ 1998; 76 (Suppl 2): 22–25.
	
11	 Papania MJ, Orenstein WA. Defining and
assessing measles elimination goals.
J Infect Dis 2004; 189 (Suppl 1): S23–S26.
	
12	 Baker M, Wilson N, Hendy S, et al. The
need for a robust scientific definition for
the elimination of COVID-­
19 from New
Zealand. Public Health Expert 2020; 5
May. https://blogs.otago.ac.nz/pubhe​
althe​xpert/​2020/05/05/the-need-for-a-
robust-scien​tific-defin​ition-for-the-elimi​
nation-of-covid-19-from-new-zeala​nd/
(viewed July 2020).
	
13	 Wilson N, Telfar Barnard L, Kvalsvig
A, et al. Potential health impacts
from the COVID-19 pandemic for New
Zealand if eradication fails: report to
the NZ Ministry of Health. Wellington:
University of Otago Wellington, 2020.
	
14	 Wilson N, Barnard LT, Summers JA, et al.
Differential mortality rates by ethnicity
in 3 influenza pandemics over a century,
New Zealand. Emerg Infect Dis 2012; 18:
71–77.
	
15	 Kissler SM, Tedijanto C, Goldstein E, et al.
Projecting the transmission dynamics of
SARS-­
CoV-­
2 through the postpandemic
period. Science 2020; 368: 860–868.
	
16	 Ferretti L, Wymant C, Kendall M, et al.
Quantifying SARS-­CoV-­2 transmission
suggests epidemic control with digital
contact tracing. Science 2020; 368:
eabb6936.
	
17	 Howell BE, Potgieter PH. A tale of
two contact-­
tracing apps – comparing
Australia’s COVIDSafe and New Zealand’s
NZ COVID Tracer. SSRN 2020; 15 June.
https://papers.ssrn.com/sol3/papers.
cfm?abstr​act_id=3612596 (viewed July
2020).
	
18	 He X, Lau EHY, Wu P, et al. Temporal
dynamics in viral shedding and
transmissibility of COVID-­
19. Nat Med
2020; 26: 672–675.
	
19	 Kvalsvig A, Wilson N, Chan L, et al. Mass
masking: an alternative to a second
lockdown in Aotearoa. N Z Med J 2020;
133: 8–13.
	
20	 Horton R. Coronavirus is the greatest
global science policy failure in a
generation. The Guardian 2020; 9 Apr
https://www.thegu​ardian.com/comme​
ntisf​ree/2020/apr/09/deadly-virus-brita​
in-failed-prepa​re-mers-sars-ebola-coron​
avirus (viewed June 2020). ■
View publication stats
View publication stats

More Related Content

What's hot

What's hot (20)

The covid 19- a mystery disease
The covid 19- a mystery diseaseThe covid 19- a mystery disease
The covid 19- a mystery disease
 
Epidemics and Epidemic Investigation
Epidemics and Epidemic InvestigationEpidemics and Epidemic Investigation
Epidemics and Epidemic Investigation
 
SARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern OmicronSARS-CoV-2 Variant of Concern Omicron
SARS-CoV-2 Variant of Concern Omicron
 
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
 
Coronavirus ( COVID19 ) CSD ICT Center Global curriculum
Coronavirus ( COVID19 ) CSD ICT Center Global curriculumCoronavirus ( COVID19 ) CSD ICT Center Global curriculum
Coronavirus ( COVID19 ) CSD ICT Center Global curriculum
 
Coronavirus global report covid 19
Coronavirus global report covid 19Coronavirus global report covid 19
Coronavirus global report covid 19
 
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA:  What is new?05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA:  What is new?
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
 
Covid- 19 Vaccines
Covid- 19 VaccinesCovid- 19 Vaccines
Covid- 19 Vaccines
 
COVID-19 Infection Prevention and Control (IPC)
COVID-19 Infection Prevention and Control (IPC)COVID-19 Infection Prevention and Control (IPC)
COVID-19 Infection Prevention and Control (IPC)
 
COVID-19
COVID-19COVID-19
COVID-19
 
Defeating COVID-19
Defeating COVID-19Defeating COVID-19
Defeating COVID-19
 
Corona virus
Corona virusCorona virus
Corona virus
 
WEBINAR REPLAY: One Year On: COVID-19, Rapid Testing, Vaccines, and a Return ...
WEBINAR REPLAY: One Year On: COVID-19, Rapid Testing, Vaccines, and a Return ...WEBINAR REPLAY: One Year On: COVID-19, Rapid Testing, Vaccines, and a Return ...
WEBINAR REPLAY: One Year On: COVID-19, Rapid Testing, Vaccines, and a Return ...
 
Corona in children third wave
Corona in children third waveCorona in children third wave
Corona in children third wave
 
Coronavirus
CoronavirusCoronavirus
Coronavirus
 
TRAINING NURSES IN CARING THE PATIENTS IN EPIDEMICS AND PANDEMICS by D...
TRAINING NURSES IN  CARING THE      PATIENTS IN EPIDEMICS AND PANDEMICS  by D...TRAINING NURSES IN  CARING THE      PATIENTS IN EPIDEMICS AND PANDEMICS  by D...
TRAINING NURSES IN CARING THE PATIENTS IN EPIDEMICS AND PANDEMICS by D...
 
Dr Senjuti Saha @ MRF's Meningitis and Septicaemia 2019
Dr Senjuti Saha @ MRF's Meningitis and Septicaemia 2019Dr Senjuti Saha @ MRF's Meningitis and Septicaemia 2019
Dr Senjuti Saha @ MRF's Meningitis and Septicaemia 2019
 
Introduction to covid 19
Introduction to covid 19 Introduction to covid 19
Introduction to covid 19
 
REVIEW OF EVIDENCE: HETEROLOGOUS AND HOMOLOGOUS BOOSTING FOR SINOVAC PRIMARY ...
REVIEW OF EVIDENCE: HETEROLOGOUS AND HOMOLOGOUS BOOSTING FOR SINOVAC PRIMARY ...REVIEW OF EVIDENCE: HETEROLOGOUS AND HOMOLOGOUS BOOSTING FOR SINOVAC PRIMARY ...
REVIEW OF EVIDENCE: HETEROLOGOUS AND HOMOLOGOUS BOOSTING FOR SINOVAC PRIMARY ...
 
Covid 19-antibodies-pdf
Covid 19-antibodies-pdfCovid 19-antibodies-pdf
Covid 19-antibodies-pdf
 

Similar to New zealands covid_-19_elimination_strategy

Critical preparedness, readiness and response actions
Critical preparedness, readiness and response actionsCritical preparedness, readiness and response actions
Critical preparedness, readiness and response actions
ssuser7bf75d
 
Untitled presvbnentation.pdf
Untitled presvbnentation.pdfUntitled presvbnentation.pdf
Untitled presvbnentation.pdf
yhghmm
 

Similar to New zealands covid_-19_elimination_strategy (20)

CHAPTER-II-1.docx
CHAPTER-II-1.docxCHAPTER-II-1.docx
CHAPTER-II-1.docx
 
Critical preparedness, readiness and response actions
Critical preparedness, readiness and response actionsCritical preparedness, readiness and response actions
Critical preparedness, readiness and response actions
 
Dadang hermansyah tik smanpa bahan penanganan virus covid 10 maret 2020
Dadang hermansyah tik smanpa bahan penanganan virus covid 10 maret 2020Dadang hermansyah tik smanpa bahan penanganan virus covid 10 maret 2020
Dadang hermansyah tik smanpa bahan penanganan virus covid 10 maret 2020
 
Covid tto reino_unido Dr. Freddy Flores Malpartida
Covid tto reino_unido Dr. Freddy Flores MalpartidaCovid tto reino_unido Dr. Freddy Flores Malpartida
Covid tto reino_unido Dr. Freddy Flores Malpartida
 
Widespread community-spread-of-sars-co v-2-is-damaging-to-health-society-and-...
Widespread community-spread-of-sars-co v-2-is-damaging-to-health-society-and-...Widespread community-spread-of-sars-co v-2-is-damaging-to-health-society-and-...
Widespread community-spread-of-sars-co v-2-is-damaging-to-health-society-and-...
 
Covid-19.pdf
Covid-19.pdfCovid-19.pdf
Covid-19.pdf
 
vaksin.pdf
vaksin.pdfvaksin.pdf
vaksin.pdf
 
Covid resource india 20th april 2020 report
Covid resource india  20th april 2020 reportCovid resource india  20th april 2020 report
Covid resource india 20th april 2020 report
 
Assignment on Covid 19 | Tutors India.pptx
Assignment on Covid 19 | Tutors India.pptxAssignment on Covid 19 | Tutors India.pptx
Assignment on Covid 19 | Tutors India.pptx
 
Covid19, varient overview
Covid19,  varient  overviewCovid19,  varient  overview
Covid19, varient overview
 
Managment Of Long Term Care In Era Covid-19
Managment Of Long Term Care In Era Covid-19Managment Of Long Term Care In Era Covid-19
Managment Of Long Term Care In Era Covid-19
 
Untitled presvbnentation.pdf
Untitled presvbnentation.pdfUntitled presvbnentation.pdf
Untitled presvbnentation.pdf
 
COVID-19 Pandemic.pptx
COVID-19 Pandemic.pptxCOVID-19 Pandemic.pptx
COVID-19 Pandemic.pptx
 
COVID.pdf
COVID.pdfCOVID.pdf
COVID.pdf
 
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
 
keynote speaker sa safety symposium Nicola spurrier
 keynote speaker sa safety symposium  Nicola spurrier keynote speaker sa safety symposium  Nicola spurrier
keynote speaker sa safety symposium Nicola spurrier
 
COVID VACCINE-2.pptx
COVID VACCINE-2.pptxCOVID VACCINE-2.pptx
COVID VACCINE-2.pptx
 
Impact of covid 19 on oncology
Impact of covid 19 on oncologyImpact of covid 19 on oncology
Impact of covid 19 on oncology
 
Covid 19 Strategic preparedness and response plan.pptx
Covid 19 Strategic preparedness and response plan.pptxCovid 19 Strategic preparedness and response plan.pptx
Covid 19 Strategic preparedness and response plan.pptx
 
COVID-19: towards controlling of a pandemic
COVID-19: towards controlling of a pandemicCOVID-19: towards controlling of a pandemic
COVID-19: towards controlling of a pandemic
 

Recently uploaded

Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 QuinolineUnit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
AarishRathnam1
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
claviclebrown44
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Abortion pills in Kuwait Cytotec pills in Kuwait
 

Recently uploaded (20)

Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 QuinolineUnit 4 Pharmaceutical Organic Chemisty 3 Quinoline
Unit 4 Pharmaceutical Organic Chemisty 3 Quinoline
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024
 
Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptx
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
 
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptxGross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
Gross Anatomy and Histology of Tongue by Dr. Rabia Inam Gandapore.pptx
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptxNegative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw material
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
Benefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdfBenefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdf
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
 

New zealands covid_-19_elimination_strategy

  • 1. See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/343648002 New Zealand's COVID ‐19 elimination strategy Article  in  The Medical journal of Australia · August 2020 DOI: 10.5694/mja2.50735 CITATIONS 40 READS 328 3 authors, including: Some of the authors of this publication are also working on these related projects: COVID-19 Pandemic View project Early Clearance of Mycobacterium tuberculosis View project Amanda Jane Kvalsvig 56 PUBLICATIONS   1,015 CITATIONS    SEE PROFILE Ayesha Verrall University of Otago 38 PUBLICATIONS   729 CITATIONS    SEE PROFILE All content following this page was uploaded by Amanda Jane Kvalsvig on 13 May 2021. The user has requested enhancement of the downloaded file.
  • 2. MJA 2020 1 Perspective New Zealand’s COVID-­ 19 elimination strategy Compared with the mitigation and suppression approaches of most Western countries, elimination can minimise direct health effects and offer an early return to social and economic activity O n 23 March 2020, New Zealand committed to an elimination strategy in response to the coronavirus disease 2019 (COVID-­ 19) pandemic. Prime Minister Jacinda Ardern announced that on 26 March, NZ would commence an intense lockdown of the country (the highest level of a four-­ level response framework1 ). At the time, NZ had just over 100 COVID-­ 19 cases and no deaths, so this “go early, go hard” approach surprised many. However, there were compelling reasons for NZ to pursue elimination.2 In this article we describe why an elimination strategy made sense for NZ, the distinguishing features of this approach, some of the challenges and how they can be overcome, and where we go from here. Elimination and other strategic choices Until early March 2020, the NZ response to COVID-­ 19 followed the existing pandemic plan, which was based on a mitigation approach for managing pandemic influenza.3 The plan includes steps designed to slow entry of the pandemic, prevent initial spread and then apply physical distancing measures progressively to flatten the curve and avoid overwhelming health services. Because pandemic influenza cannot be contained (except by extreme measures such as total border closure), there was a presumption that case-­ and contact-­ based management would fail and the country would inevitably progress to widespread community transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most Western countries across Europe and North America were following the mitigation approach. However, it was performing poorly, with COVID-­ 19 cases overwhelming health services. These countries were then switching to a suppression strategy.4 This strategy involved intense physical distancing and travel restrictions (lockdowns) to suppress virus transmission. A few countries were continuing with a version of mitigation labelled “herd immunity”, by which they planned to manage the rate of infection in such a way as to avoid overwhelming the health care system and build up enough recovered and likely immune people in the population to ultimately interrupt virus transmission. This approach proved difficult to manage and was largely abandoned (except perhaps by Sweden). Most low and middle income countries could do very little to manage the pandemic except by applying limited mitigation measures. Vietnam was a notable exception, implementing stringent control measures including quarantine, contact tracing, border controls, school closures and traffic restrictions while case numbers were still low. A number of island states, such as Samoa, Tonga and the Cook Islands, adopted an exclusion approach, primarily by closing their borders to incoming travellers. By early March the evidence base for elimination was growing, with the increasing realisation that COVID-­ 19 was markedly different to pandemic influenza in terms of its transmission dynamics.5 A watershed moment was the report of the World Health Organization joint mission to China, which confirmed that the pandemic there had been contained even after widespread community transmission had commenced.6 There was also strong evidence for early success of the elimination approach in Taiwan,7 Hong Kong8 and South Korea.9 The concept of elimination is well known to infectious disease epidemiologists.10 It refers to the reduction of the incidence of a disease to zero in a defined geographical area. While absence of disease is the ultimate goal, elimination criteria for highly infectious diseases such as measles allow for occasional outbreaks or imported cases, provided they are stamped out within a defined time period.11 By contrast, eradication means that the incidence of a disease has been reduced to zero at the global level, at least outside laboratories. There is no established definition for COVID-­ 19 elimination. Preliminary thinking suggests that such a definition would need to include a defined period of absence of new cases (perhaps 28 days, which is twice the maximum 14-­ day incubation period).12 This definition would also require a high performing surveillance system and would exclude cases infected outside the country and detected in new arrivals while under isolation or quarantine.12 By late July 2020, NZ had experienced no instances of community-­ based transmission for more than 80 days and could be considered to have attained elimination. This status can take weeks or even months to achieve, and countries could potentially move in and out of this state depending on their success in containing the pandemic. Benefits and costs of elimination At the time NZ chose an elimination strategy, the exact nature of this response and its full justification had not been articulated. The health impact of a poorly contained pandemic had been modelled using a range of scenarios,13 demonstrating clear health gains if a widespread pandemic could be prevented in NZ. There was also a concern to avoid repeating the catastrophic impact of previous influenza pandemics on Māori and to protect neighbouring Pacific Islands.14 University of Otago, Wellington, NZ. michael.baker@ otago.ac.nz doi: 10.5694/mja2.50735 Michael G Baker Amanda Kvalsvig Ayesha J Verrall
  • 3. 2 Perspective MJA 2020 2 The net economic consequences of an elimination strategy were uncertain and extremely difficult to estimate. An additional challenge was that both the pandemic and its response were likely to have a disproportionate impact on disadvantaged populations. While an elimination strategy would have huge economic and social costs, the alternatives (suppression and mitigation) would almost certainly have been far more damaging because of the need to continue costly physical distancing measures until a vaccine or other intervention became available. An advantage of a successful elimination strategy was that it would provide a medium term exit path for a return to domestic economic activity without the constraints of circulating SARS-­ CoV-­ 2. Neither mitigation nor suppression provide a firm exit strategy, particularly given major uncertainties about coronavirus immunity and the potential for ongoing epidemic transmission for months to years under some scenarios.15 As with all COVID-­ 19 strategies, the ultimate exit path will depend on developing effective vaccines and therapeutics. Components of elimination and their implementation Elimination requires an array of control measures tailored to local needs and to the transmission characteristics of the organism concerned. For COVID-­ 19, the major components are similar to those used for pandemic control more generally. The main difference is the intensity and timing of their application (Box). COVID-­ 19 elimination requires a very strong emphasis on border management to keep the virus out. That intervention would usually be combined with case and contact management to stamp out transmission, along with highly developed surveillance and testing to rapidly identify cases and outbreaks. If started early, these measures may be sufficient for elimination without the need for lockdowns, as was achieved in Taiwan. An elimination strategy requires highly functioning public health infrastructure. Similar to many other countries, NZ has supplemented traditional approaches with newer tools, such as the use of digital technology to speed up contact tracing.16 The NZ COVID Tracer app is now operational,17 although it has yet to be used for contact tracing given the lack of community cases. Additional surveillance approaches can be used to provide increased assurance of elimination (eg, sentinel surveillance, sewage testing). However, even in the presence of a highly sophisticated surveillance system, transmission will continue if isolation and quarantine adherence is suboptimal. Barriers to successful elimination and how to overcome them The COVID-­ 19 pandemic was halted in China, demonstrating that there are no absolute biological barriers to its elimination.6 Having no important animal or environmental reservoirs is a necessary condition, and this appears to be the case for SARS-­ CoV-­ 2 (although its actual origin in nature has not been determined, so cases could in theory arise from this source). The combination of high infectiousness and presymptomatic transmission poses challenges for control.18 Fortunately, its relatively long incubation period (about 5 days) makes contact tracing and quarantining effective, unlike for influenza.5 Components of pandemic control and features that distinguish an elimination strategy from mitigation and suppression Pandemic control system component Feature that distinguishes elimination from mitigation and suppression Planning, coordination and logistics Potentially increased to manage intense elimination measures, including dedicated agencies, infrastructure and trained public health workforce Border management, including exclusion, quarantine Increased intensity is critical to creating and sustaining elimination Case, contact and outbreak management, including case isolation and contact tracing and quarantine Increased intensity is critical to creating and sustaining elimination, including expanded testing capacity and contact tracing systems and workforce Disease surveillance, including high volume laboratory testing and sentinel surveillance Increased intensity is critical to creating and sustaining elimination, including strong emphasis on rapid, sensitive case identification and additional methods to confirm elimination Physical distancing and movement restriction at various levels (up to lockdown) Ability to introduce early and intensely to suppress community transmissions and outbreaks Public communication to improve hand washing, cough etiquette, mask wearing, physical distancing Potentially increased to communicate intense elimination measures Protecting vulnerable populations Similar, but duration will be shorter if elimination is successful Primary care capacity Adapted to increase testing capacity Hospital capacity (eg, expansion of intensive care unit and ventilator capacity) Similar, but duration will be shorter and demand less intense if elimination is successful Protecting health care workers Similar, but demand will be less intense if elimination is successful Research and evaluation Potentially increased given limited evidence base for elimination measures
  • 4. MJA 2020 3 Perspective MJA 2020 3 Changing human behaviour to reduce transmission is challenging with a virus as infectious as SARS-­ CoV-­ 2. This is why mandated extreme physical distancing and movement control (lockdown) may be needed. The intense lockdown carried out in NZ suppressed transmission and gave the country time to expand border controls, improve contact tracing, and undertake large scale testing. Coming out of lockdown (which began progressively on 28 April) must be managed carefully, as the goal is to emerge into a country that is free from community transmission (unlike the lockdowns in countries pursuing mitigation or suppression). Widespread use of face masks was not a feature of the NZ strategy but might in future reduce the need for lockdowns.19 Successful implementation of an elimination strategy requires early risk assessment, effective response planning, infrastructure, resources and political will. The global response to SARS-­ CoV-­ 2 has been described as the “greatest science policy failure of our generation”.20 An elimination strategy could potentially have been widely used to contain COVID-­ 19 and protect populations in countries across the globe. Where to from here? NZ and Australia appear to have joined a small group of countries and jurisdictions pursuing an explicit, or implied, elimination goal, albeit by different strategies. Others including mainland China, Hong Kong, Taiwan, South Korea, Vietnam and a number of small island states and territories. This set of countries is likely to expand in the future. It is not hard to imagine travel between them being relaxed once the risks are well understood and can be managed. It may be time for these countries to actively share knowledge and evidence about the approaches that are supporting them to contain and eliminate COVID-­ 19. There are multiple potential future scenarios. By pursuing and maintaining an elimination strategy, countries can prevent disease and death from COVID-­ 19 and avoid further exacerbation of existing health inequities. They can also move from having to manage ongoing pandemic transmission within their populations to being able to make informed strategic choices about prevention and control options such as vaccines and therapeutics as they become available. Acknowledgements: We thank our many colleagues who have contributed to development of the NZ elimination strategy, notably Professor Nick Wilson at the University of Otago, Wellington. We also acknowledge funding support from the Health Research Council of NZ (20/1066), which did not have any role in the planning, writing or publication of the work or the decision to publish. Competing interests: No relevant disclosures. Provenance: Commissioned; externally peer reviewed. ■ © 2020 AMPCo Pty Ltd References are available online.
  • 5. 4 Perspective MJA 2020 3.e1 1 New Zealand Government. New Zealand COVID-19 alert levels summary. https:// covid​19.govt.nz/asset​s/COVID_Alert- levels_v2.pdf (viewed June 2020). 2 Baker M, Kvalsvig A, Verrall A, et al. New Zealand’s elimination strategy for the COVID-­ 19 pandemic and what is required to make it work. N Z Med J 2020; 133: 10–14. 3 Ministry of Health. New Zealand Influenza Pandemic Plan: a framework for action. 2nd ed. Wellington: Ministry of Health, 2017. https://www.health. govt.nz/syste​m/files/​docum​ents/publi​ catio​ns/influ​enza-pande​mic-plan-frame​ work-action-2nd-edn-aug17.pdf (viewed June 2020). 4 Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. London: Imperial College London, 2020. https://spiral.imper​ial.ac.uk:8443/handl​ e/10044/​1/77482 (viewed June 2020). 5 Anderson RM, Heesterbeek H, Klinkenberg D, et al. How will country-­ based mitigation measures influence the course of the COVID-­ 19 epidemic? Lancet 2020; 395: 931–934. 6 World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16-24 February 2020. Geneva: WHO, 2020. https://www. who.int/docs/defau​lt-sourc​e/coron​aviru​ se/who-china-joint-missi​on-on-covid-19- final-report.pdf (viewed July 2020). 7 Wang CJ, Ng CY, Brook RH. Response to COVID-­ 19 in Taiwan: Big Data analytics, new technology, and proactive testing. JAMA 2020; 323: 1341–1342. 8 Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-­ pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health 2020; 5: e279–e288. 9 Kang J, Jang YY, Kim J, et al. South Korea’s responses to stop the COVID-­ 19 pandemic. Am J Infect Control 2020;. https://doi.org/10.1016/j.ajic.2020.06.003 [Epub ahead of print]. 10 Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998; 76 (Suppl 2): 22–25. 11 Papania MJ, Orenstein WA. Defining and assessing measles elimination goals. J Infect Dis 2004; 189 (Suppl 1): S23–S26. 12 Baker M, Wilson N, Hendy S, et al. The need for a robust scientific definition for the elimination of COVID-­ 19 from New Zealand. Public Health Expert 2020; 5 May. https://blogs.otago.ac.nz/pubhe​ althe​xpert/​2020/05/05/the-need-for-a- robust-scien​tific-defin​ition-for-the-elimi​ nation-of-covid-19-from-new-zeala​nd/ (viewed July 2020). 13 Wilson N, Telfar Barnard L, Kvalsvig A, et al. Potential health impacts from the COVID-19 pandemic for New Zealand if eradication fails: report to the NZ Ministry of Health. Wellington: University of Otago Wellington, 2020. 14 Wilson N, Barnard LT, Summers JA, et al. Differential mortality rates by ethnicity in 3 influenza pandemics over a century, New Zealand. Emerg Infect Dis 2012; 18: 71–77. 15 Kissler SM, Tedijanto C, Goldstein E, et al. Projecting the transmission dynamics of SARS-­ CoV-­ 2 through the postpandemic period. Science 2020; 368: 860–868. 16 Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-­CoV-­2 transmission suggests epidemic control with digital contact tracing. Science 2020; 368: eabb6936. 17 Howell BE, Potgieter PH. A tale of two contact-­ tracing apps – comparing Australia’s COVIDSafe and New Zealand’s NZ COVID Tracer. SSRN 2020; 15 June. https://papers.ssrn.com/sol3/papers. cfm?abstr​act_id=3612596 (viewed July 2020). 18 He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-­ 19. Nat Med 2020; 26: 672–675. 19 Kvalsvig A, Wilson N, Chan L, et al. Mass masking: an alternative to a second lockdown in Aotearoa. N Z Med J 2020; 133: 8–13. 20 Horton R. Coronavirus is the greatest global science policy failure in a generation. The Guardian 2020; 9 Apr https://www.thegu​ardian.com/comme​ ntisf​ree/2020/apr/09/deadly-virus-brita​ in-failed-prepa​re-mers-sars-ebola-coron​ avirus (viewed June 2020). ■ View publication stats View publication stats